RÉSUMÉ
Favipiravir, a broad-spectrum RNA-dependent RNA polymerase inhibitor, is currently being evaluated in preclinical and clinical studies for the treatment of various infectious diseases including COVID-19. We developed an ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) assay for the quantification of favipiravir and its hydroxide metabolite (M1), in human and hamster biological matrices. Analytes were separated on an Acquity UPLC HSS T3 column (2.1 × 100 mm, 1.8 µm) after a simple protein precipitation with acetonitrile. The mobile phase consisted of water and methanol, each containing 0.05% formic acid. Experiments were performed using electrospray ionization in the positive and negative ion mode, with protonated molecules used as the precursor ion and a total run time of 6 min. The MS/MS response was linear over the concentration ranges from 0.5-100 µg/ml for favipiravir and 0.25-30 µg/ml for M1. Intra- and inter-day accuracy and precision were within the recommended limits of the European Medicines Agency guidelines. No significant matrix effect was observed, and the method was successfully applied to inform favipiravir dose adjustments in six immunocompromised children with severe RNA viral infections. In conclusion, the UPLC-MS/MS assay is suitable for quantification of favipiravir over a wide range of dosing regimens, and can easily be adapted to other matrices and species.
Sujet(s)
COVID-19 , Spectrométrie de masse en tandem , Enfant , Humains , Cricetinae , Chromatographie en phase liquide , Spectrométrie de masse en tandem/méthodes , Chromatographie en phase liquide à haute performance/méthodes , HydroxydesRÉSUMÉ
BACKGROUND: To address the emergence of SARS-CoV-2, multiple clinical trials in humans were rapidly started, including those involving an oral treatment by nitazoxanide, despite no or limited pre-clinical evidence of antiviral efficacy. METHODS: In this work, we present a complete pre-clinical evaluation of the antiviral activity of nitazoxanide against SARS-CoV-2. FINDINGS: First, we confirmed the in vitro efficacy of nitazoxanide and tizoxanide (its active metabolite) against SARS-CoV-2. Then, we demonstrated nitazoxanide activity in a reconstructed bronchial human airway epithelium model. In a SARS-CoV-2 virus challenge model in hamsters, oral and intranasal treatment with nitazoxanide failed to impair viral replication in commonly affected organs. We hypothesized that this could be due to insufficient diffusion of the drug into organs of interest. Indeed, our pharmacokinetic study confirmed that concentrations of tizoxanide in organs of interest were always below the in vitro EC50. INTERPRETATION: These preclinical results suggest, if directly applicable to humans, that the standard formulation and dosage of nitazoxanide is not effective in providing antiviral therapy for Covid-19. FUNDING: This work was supported by the Fondation de France "call FLASH COVID-19", project TAMAC, by "Institut national de la santé et de la recherche médicale" through the REACTing (REsearch and ACTion targeting emerging infectious diseases), by REACTING/ANRS MIE under the agreement No. 21180 ('Activité des molécules antivirales dans le modèle hamster'), by European Virus Archive Global (EVA 213 GLOBAL) funded by the European Union's Horizon 2020 research and innovation program under grant agreement No. 871029 and DNDi under support by the Wellcome Trust Grant ref: 222489/Z/21/Z through the COVID-19 Therapeutics Accelerator".
Sujet(s)
Traitements médicamenteux de la COVID-19 , SARS-CoV-2 , Animaux , Antiviraux/pharmacologie , Antiviraux/usage thérapeutique , Cricetinae , Humains , Composés nitrés , ThiazolesRÉSUMÉ
Following the emergence of SARS-CoV-2, the search for an effective and rapidly available treatment was initiated worldwide based on repurposing of available drugs. Previous reports described the antiviral activity of certain tyrosine kinase inhibitors (TKIs) targeting the Abelson kinase 2 against pathogenic coronaviruses. Imatinib, one of them, has more than twenty years of safe utilization for the treatment of hematological malignancies. In this context, Imatinib was rapidly evaluated in clinical trials against Covid-19. Here, we present the pre-clinical evaluation of imatinib in multiple models. Our results indicated that imatinib and another TKI, the masitinib, exhibit an antiviral activity in VeroE6 cells. However, imatinib was inactive in a reconstructed bronchial human airway epithelium model. In vivo, imatinib therapy failed to impair SARS-CoV-2 replication in a golden Syrian hamster model despite high concentrations in plasma and in the lung. Overall, these results do not support the use of imatinib and similar TKIs as antivirals in the treatment of Covid-19.
Sujet(s)
Antiviraux/pharmacologie , Traitements médicamenteux de la COVID-19 , Mésilate d'imatinib/pharmacologie , SARS-CoV-2/effets des médicaments et des substances chimiques , Animaux , COVID-19/épidémiologie , COVID-19/virologie , Lignée cellulaire , Chlorocebus aethiops , Évaluation préclinique de médicament , Repositionnement des médicaments , Antienzymes/pharmacologie , Épithélium , Femelle , Humains , Poumon/anatomopathologie , Mâle , Mesocricetus , Cellules Vero , Réplication virale/effets des médicaments et des substances chimiquesRÉSUMÉ
Despite no or limited pre-clinical evidence, repurposed drugs are massively evaluated in clinical trials to palliate the lack of antiviral molecules against SARS-CoV-2. Here we use a Syrian hamster model to assess the antiviral efficacy of favipiravir, understand its mechanism of action and determine its pharmacokinetics. When treatment is initiated before or simultaneously to infection, favipiravir has a strong dose effect, leading to reduction of infectious titers in lungs and clinical alleviation of the disease. Antiviral effect of favipiravir correlates with incorporation of a large number of mutations into viral genomes and decrease of viral infectivity. Antiviral efficacy is achieved with plasma drug exposure comparable with those previously found during human clinical trials. Notably, the highest dose of favipiravir tested is associated with signs of toxicity in animals. Thereby, pharmacokinetic and tolerance studies are required to determine whether similar effects can be safely achieved in humans.
Sujet(s)
Amides/pharmacologie , Antiviraux/pharmacologie , Traitements médicamenteux de la COVID-19 , Pyrazines/pharmacologie , SARS-CoV-2/effets des médicaments et des substances chimiques , Animaux , COVID-19/virologie , Chlorocebus aethiops , Cricetinae , Modèles animaux de maladie humaine , Femelle , Génome viral , Poumon/virologie , Mesocricetus , SARS-CoV-2/génétique , Cellules Vero , Charge virale/effets des médicaments et des substances chimiquesRÉSUMÉ
ABSTRACT: Therapeutic drug monitoring of hydroxychloroquine (HCQ) has been recommended to optimize the treatment of patients with COVID-19. The authors describe an ultrahigh-performance liquid chromatography tandem spectrometry method developed in a context of emergency, to analyze HCQ in both human plasma and blood samples. After adding the labeled internal standard and simple protein precipitation, plasma samples were analyzed using a C18 column. Blood samples required evaporation before analysis. The total chromatographic run time was 4 minutes (including 1.5 minutes of column equilibration). The assay was linear over the calibration range (r2 > 0.99) and up to 1.50 mcg/mL for the plasma samples (5.00 mcg/mL for the blood matrix). The limit of quantification was 0.0150 mcg/mL for plasma samples (0.05 mcg/mL blood matrix) with accuracy and precision ranging from 91.1% to 112% and from 0.750% to 11.1%, respectively. Intraday and interday precision and accuracy values were within 15.0%. No significant matrix effect was observed in the plasma or blood samples. This method was successfully applied to patients treated for COVID-19 infection. A simple and rapid ultrahigh-performance liquid chromatography tandem spectrometry method adapted to HCQ therapeutic drug monitoring in the context of SARS-CoV-2 infection was successfully developed and validated.
Sujet(s)
Traitements médicamenteux de la COVID-19 , Surveillance des médicaments/normes , Services des urgences médicales/normes , Hydroxychloroquine/sang , Spectrométrie de masse en tandem/normes , Antirhumatismaux/sang , Antirhumatismaux/usage thérapeutique , COVID-19/sang , Chromatographie en phase liquide à haute performance/méthodes , Chromatographie en phase liquide à haute performance/normes , Chromatographie en phase liquide/méthodes , Chromatographie en phase liquide/normes , Surveillance des médicaments/méthodes , Services des urgences médicales/méthodes , Humains , Hydroxychloroquine/usage thérapeutique , Pandémies , Spectrométrie de masse en tandem/méthodesRÉSUMÉ
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the globe after its emergence in Wuhan in December 2019. With no specific therapeutic and prophylactic options available, the virus has infected millions of people of which more than half a million succumbed to the viral disease, COVID-19. The urgent need for an effective treatment together with a lack of small animal infection models has led to clinical trials using repurposed drugs without preclinical evidence of their in vivo efficacy. We established an infection model in Syrian hamsters to evaluate the efficacy of small molecules on both infection and transmission. Treatment of SARS-CoV-2-infected hamsters with a low dose of favipiravir or hydroxychloroquine with(out) azithromycin resulted in, respectively, a mild or no reduction in virus levels. However, high doses of favipiravir significantly reduced infectious virus titers in the lungs and markedly improved lung histopathology. Moreover, a high dose of favipiravir decreased virus transmission by direct contact, whereas hydroxychloroquine failed as prophylaxis. Pharmacokinetic modeling of hydroxychloroquine suggested that the total lung exposure to the drug did not cause the failure. Our data on hydroxychloroquine (together with previous reports in macaques and ferrets) thus provide no scientific basis for the use of this drug in COVID-19 patients. In contrast, the results with favipiravir demonstrate that an antiviral drug at nontoxic doses exhibits a marked protective effect against SARS-CoV-2 in a small animal model. Clinical studies are required to assess whether a similar antiviral effect is achievable in humans without toxic effects.
Sujet(s)
Amides/usage thérapeutique , Antiviraux/usage thérapeutique , Betacoronavirus/effets des médicaments et des substances chimiques , Hydroxychloroquine/usage thérapeutique , Pyrazines/usage thérapeutique , Amides/pharmacocinétique , Animaux , Chlorocebus aethiops , Infections à coronavirus/traitement médicamenteux , Infections à coronavirus/virologie , Cricetinae , Modèles animaux de maladie humaine , Transmission de maladie infectieuse/prévention et contrôle , Relation dose-effet des médicaments , Évaluation préclinique de médicament , Femelle , Hydroxychloroquine/pharmacocinétique , Poumon/effets des médicaments et des substances chimiques , Poumon/anatomopathologie , Poumon/virologie , Pyrazines/pharmacocinétique , SARS-CoV-2 , Résultat thérapeutique , Cellules Vero , Charge virale/effets des médicaments et des substances chimiques , Traitements médicamenteux de la COVID-19RÉSUMÉ
We report the isolation and genomic characterization of a Sapelovirus A strain, or porcine sapelovirus (PSV), from a diarrheic Corsican piglet in France. It shares 87% nucleotide identity with a 2014 German isolate.